{
    "nct_id": "NCT03446001",
    "title": "Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of TRx0237 Monotherapy in Subjects With Alzheimer's Disease Followed by a 12-Month Open-Label Treatment",
    "status": "COMPLETED",
    "last_update_time": "2025-08-14",
    "description_brief": "The purpose of this study is to determine the safety and efficacy of TRx0237 16 mg/day and 8 mg/day in the treatment of subjects with Alzheimer's Disease compared to placebo. In addition, an open-label, delayed-start phase is included to demonstrate a disease-modifying effect of TRx0237.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE3"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": {
        "participantFlowModule": {
            "groups": [
                {
                    "id": "FG000",
                    "title": "Control",
                    "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily during the double-blind phase, then switched to TRx0237 16 mg/day during the open-label phase"
                },
                {
                    "id": "FG001",
                    "title": "TRx0237 8 mg/Day",
                    "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablet administered twice daily during the double-blind phase, then switched to TRx0237 16 mg/day during the open-label phase"
                },
                {
                    "id": "FG002",
                    "title": "TRx0237 16 mg/Day",
                    "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily during the double-blind phase, continued on TRx0237 16 mg/day during the open-label phase"
                }
            ],
            "periods": [
                {
                    "title": "Double-blind Phase",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "266"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "80"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "252"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "215"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "61"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "194"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "51"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "19"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "58"
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Open-label Phase (All TRx0237 16 mg/Day)",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "comment": "14 subjects completed an earlier version of the study protocol, in which there was no open-label phase following the double-blind phase.",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "205"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "57"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "194"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "176"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "47"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "168"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "29"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "10"
                                },
                                {
                                    "groupId": "FG002",
                                    "numSubjects": "26"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Control",
                    "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                },
                {
                    "id": "BG001",
                    "title": "TRx0237 8 mg/Day",
                    "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablet administered twice daily"
                },
                {
                    "id": "BG002",
                    "title": "TRx0237 16 mg/Day",
                    "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                },
                {
                    "id": "BG003",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "266"
                        },
                        {
                            "groupId": "BG001",
                            "value": "80"
                        },
                        {
                            "groupId": "BG002",
                            "value": "252"
                        },
                        {
                            "groupId": "BG003",
                            "value": "598"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Continuous",
                    "paramType": "MEAN",
                    "dispersionType": "STANDARD_DEVIATION",
                    "unitOfMeasure": "years",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "72.4",
                                            "spread": "8.3"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "71.8",
                                            "spread": "8.1"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "71.9",
                                            "spread": "8.6"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "72.1",
                                            "spread": "8.4"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "153"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "49"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "161"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "363"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "113"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "91"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "235"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Race (NIH/OMB)",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "American Indian or Alaska Native",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "0"
                                        }
                                    ]
                                },
                                {
                                    "title": "Asian",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Native Hawaiian or Other Pacific Islander",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "1"
                                        }
                                    ]
                                },
                                {
                                    "title": "Black or African American",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "10"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "2"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "8"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "20"
                                        }
                                    ]
                                },
                                {
                                    "title": "White",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "239"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "73"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "215"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "527"
                                        }
                                    ]
                                },
                                {
                                    "title": "More than one race",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "1"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "2"
                                        }
                                    ]
                                },
                                {
                                    "title": "Unknown or Not Reported",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "16"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "3"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "27"
                                        },
                                        {
                                            "groupId": "BG003",
                                            "value": "46"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (16 mg/Day vs Control)",
                    "description": "This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the control group. The scores on this scale range from 0 to 70, with higher numbers indicating a worse outcome (greater impairment).",
                    "populationDescription": "Data analyzed using the E-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline efficacy assessment; results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline ADAS-cog11 as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "198"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "189"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.71",
                                            "lowerLimit": "0.69",
                                            "upperLimit": "2.73"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.34",
                                            "lowerLimit": "0.32",
                                            "upperLimit": "2.36"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) (16 mg/Day vs Control)",
                    "description": "This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the control group. The scores on this scale range from 0 to 78, with higher numbers indicating a better outcome (lower impairment).",
                    "populationDescription": "Data analyzed using the E-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline efficacy assessment; results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline ADCS-ADL23 as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "204"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "191"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.77",
                                            "lowerLimit": "-2.32",
                                            "upperLimit": "0.78"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.62",
                                            "lowerLimit": "-2.19",
                                            "upperLimit": "0.95"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "PRIMARY",
                    "title": "Number of Study Participants With Serious and Non-serious Adverse Events (16 mg/Day vs Control)",
                    "description": "This primary outcome measure was assessed in the TRx0237 16 mg/day group compared to the placebo group. All laboratory test or vital sign parameter abnormalities deemed clinically significant by the Investigator are to be reported as adverse events.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "266"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "252"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Number of study participants with serious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "18"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Number of study participants with non-serious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "146"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "131"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Annualized Rate of Whole Brain Atrophy (16 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 16 mg/day group compared to the control group.",
                    "populationDescription": "Data analyzed using the MI-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline MRI assessment; results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline MRI whole brain volume as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "mm3/year",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "175"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "165"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-11137.44",
                                            "lowerLimit": "-12682.86",
                                            "upperLimit": "-9592.01"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-11162.70",
                                            "lowerLimit": "-12711.43",
                                            "upperLimit": "-9613.98"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Standardized Uptake Value Ratio (SUVR) Based on Temporal Lobe 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) (16 mg/Day vs Control)",
                    "description": "This secondary outcome measure (normalized to pons) was assessed in the TRx0237 16 mg/day dose group compared to the control group, and restricted to subjects with Clinical Dementia Rating (CDR) 0.5 at Screening.",
                    "populationDescription": "Data analyzed using the PI-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline 18F-FDG-PET SUVR assessment; results reported for subjects with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (ANCOVA with fixed effects, including Baseline PET temporal lobe glucose uptake as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "ratio",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "88"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "93"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.025",
                                            "lowerLimit": "-0.036",
                                            "upperLimit": "-0.015"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.026",
                                            "lowerLimit": "-0.036",
                                            "upperLimit": "-0.016"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Annualized Rate of Temporoparietal Lobe Atrophy (16 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 16mg/day group compared to the control group.",
                    "populationDescription": "Data analyzed using the MI-MITTv5 Population (all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline MRI assessment); results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline MRI whole temporoparietal lobe volume as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "mm3/year",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 16 mg/Day",
                            "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "175"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "165"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-740.79",
                                            "lowerLimit": "-821.39",
                                            "upperLimit": "-660.19"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-711.14",
                                            "lowerLimit": "-791.96",
                                            "upperLimit": "-630.32"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11) (8 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 8 mg/day group compared to the control group. The scores on this scale range from 0 to 70, with higher numbers indicating a worse outcome (greater impairment).\n\nNote: Estimates for the Control Arm in the primary outcome and this secondary outcome are estimated using separate Mixed Models for Repeated Measures (MMRM). Thus, it is appropriate for the two models to yield two slightly different estimates for the Control Arm change as the comparator is different in each case and the model uses this information to make its estimates.",
                    "populationDescription": "Data analyzed using the E-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline efficacy assessment; results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline ADAS-cog11 as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 8 mg/Day",
                            "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "198"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "47"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "1.78",
                                            "lowerLimit": "0.79",
                                            "upperLimit": "2.77"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "1.06",
                                            "lowerLimit": "-0.89",
                                            "upperLimit": "3.01"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline on Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL23) (8 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 8 mg/day group compared to the control group. The scores on this scale range from 0 to 78, with higher numbers indicating a better outcome (lower impairment).\n\nNote: Estimates for the Control Arm in the primary outcome and this secondary outcome are estimated using separate Mixed Models for Repeated Measures (MMRM). Thus, it is appropriate for the two models to yield two slightly different estimates for the Control Arm change as the comparator is different in each case and the model uses this information to make its estimates.",
                    "populationDescription": "Data analyzed using the E-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline efficacy assessment; results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline ADCS-ADL23 as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 8 mg/Day",
                            "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "204"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "47"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.82",
                                            "lowerLimit": "-2.36",
                                            "upperLimit": "0.72"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.41",
                                            "lowerLimit": "-4.46",
                                            "upperLimit": "1.64"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Standardized Uptake Value Ratio (SUVR) Based on Temporal Lobe 18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) (8 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 8mg/day dose group compared to the control group, and restricted to subjects with Clinical Dementia Rating (CDR) 0.5 at Screening.\n\nNote: Estimates for the Control Arm in the TRx0237 16 mg/day dose group comparison and this secondary outcome are estimated using separate Mixed Models for Repeated Measures (MMRM). Thus, it is appropriate for the two models to yield two slightly different estimates for the Control Arm change as the comparator is different in each case and the model uses this information to make its estimates.",
                    "populationDescription": "Data analyzed using the PI-MITTv5 Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline 18F-FDG-PET SUVR assessment; results reported for subjects with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (ANCOVA with fixed effects, including Baseline PET temporal lobe glucose uptake as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "ratio",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 8 mg/Day",
                            "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "88"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "22"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.027",
                                            "lowerLimit": "-0.038",
                                            "upperLimit": "-0.016"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.022",
                                            "lowerLimit": "-0.041",
                                            "upperLimit": "-0.002"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change in Annualized Rate of Temporoparietal Lobe Atrophy (8 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 8 mg/day dose group compared to the control group.\n\nNote: Estimates for the Control Arm in the TRx0237 16 mg/day dose group comparison and this secondary outcome are estimated using separate Mixed Models for Repeated Measures (MMRM). Thus, it is appropriate for the two models to yield two slightly different estimates for the Control Arm change as the comparator is different in each case and the model uses this information to make its estimates.",
                    "populationDescription": "Data analyzed using the MI-MITTv5 Population (all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug and have a Baseline and at least one valid postbaseline MRI assessment); results reported for subjects in this population with Baseline and Week 52 data. Change from Baseline to Week 52 is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline MRI whole temporoparietal volume as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "mm3/year",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 8 mg/Day",
                            "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "175"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "45"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-729.55",
                                            "lowerLimit": "-806.00",
                                            "upperLimit": "-652.09"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-651.28",
                                            "lowerLimit": "-799.33",
                                            "upperLimit": "-503.24"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Open-Label Baseline on Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog11)",
                    "description": "This secondary outcome measure was assessed for the open-label period of the study comparing subjects originally randomized to placebo to subjects originally randomized to either dose of TRx0237. The scores on this scale range from 0 to 70, with higher numbers indicating a worse outcome (greater impairment).\n\nNote: It was prespecified to combine subjects who received TRx0237 8 mg/day or TRx0237 16 mg/day in the double-blind phase as early starters; thus these are combined for this comparison.",
                    "populationDescription": "Data analyzed using the ITTv5-OL Population, which includes all subjects randomized to Protocol Version 5.0+ who received at least one dose of study drug in the open-label (OL) phase; results reported for subjects in this population with a Baseline-OL value and Week 104 data (52 weeks of OL drug). Change from Baseline-OL to Week 104 (52 weeks) is included in the LSM calculation (restricted maximum likelihood-based MMRM with fixed effects, including Baseline-OL ADAS-cog11 as a covariate).",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "95% Confidence Interval",
                    "unitOfMeasure": "score on a scale",
                    "timeFrame": "104 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control to TRx0237 16 mg/Day",
                            "description": "Subjects who were randomized to the control arm in the double-blind phase and switched to TRx0237 16 mg/day in the open-label phase (late starters)"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 (Either Dose) to TRx0237 16 mg/Day",
                            "description": "Subjects who were randomized to the TRx0237 8 mg/day or TRx0237 16 mg/day arms in the double-blind phase and then TRx0237 16 mg/day in the open-label phase (early starters)"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "146"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "179"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.98",
                                            "lowerLimit": "2.01",
                                            "upperLimit": "3.95"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.58",
                                            "lowerLimit": "2.70",
                                            "upperLimit": "4.47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Study Participants With Serious and Non-serious Adverse Events (8 mg/Day vs Control)",
                    "description": "This secondary outcome measure was assessed in the TRx0237 8 mg/day group compared to the control group over 52 weeks. All laboratory test or vital sign parameter abnormalities deemed clinically significant by the Investigator were to be reported as adverse events.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "52 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control",
                            "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 8 mg/Day",
                            "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablets administered twice daily"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "266"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "80"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Number of study participants with serious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Number of study participants with nonserious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "146"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "47"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Number of Study Participants With Serious and Non-serious Adverse Events (Open-label)",
                    "description": "This secondary outcome measure was assessed for all subjects receiving TRx0237 in the open-label phase of the study (in which subjects had received TRx0237 for up to 104 weeks).\n\nNote: Subjects who received TRx0237 8 mg/day or TRx0237 16 mg/day arms in the double-blind phase are combined for this comparison as all had previously received TRx0237 as compared to those subjects in the control arm who were receiving TRx0237 for the first time in the open-label phase.",
                    "populationDescription": "A total of 7 subjects had discontinued study drug in the double-blind phase but completed this phase and continued to attend study visits in the open-label (OL) phase off-treatment. As these subjects did not receive TRX0237 16 mg/day in the OL phase, they are not included in the OL-Safety Population (N=449) and thus are not included in these comparisons.",
                    "reportingStatus": "POSTED",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "104 weeks",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Control to TRx0237 16 mg/Day",
                            "description": "Subjects who were randomized to the control arm in the double-blind phase and switched to TRx0237 16 mg/day in the open-label phase"
                        },
                        {
                            "id": "OG001",
                            "title": "TRx0237 (Either Dose) to TRx0237 16 mg/Day",
                            "description": "Subjects who were randomized to the TRx0237 8 mg/day or TRx0237 16 mg/day arms in the double-blind phase and then received TRx0237 16 mg/day in the open-label phase"
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "201"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "248"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "title": "Number of study participants with serious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "14"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "13"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Number of study participants with nonserious adverse events",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "88"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "101"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "4",
            "timeFrame": "104 weeks (2 years)",
            "description": "AEs were ascertained at each study visit by asking the subject and study partner how the subject had been since the last visit. Additionally, AEs were also reported based on study safety assessments performed at each study visit.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Double-blind Control",
                    "description": "Control: Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily",
                    "deathsNumAffected": 1,
                    "deathsNumAtRisk": 266,
                    "seriousNumAffected": 17,
                    "seriousNumAtRisk": 266,
                    "otherNumAffected": 30,
                    "otherNumAtRisk": 266
                },
                {
                    "id": "EG001",
                    "title": "Double-blind TRx0237 8 mg/Day",
                    "description": "TRx0237 8 mg/day: Oral TRx0237 4-mg tablet administered twice daily",
                    "deathsNumAffected": 0,
                    "deathsNumAtRisk": 80,
                    "seriousNumAffected": 6,
                    "seriousNumAtRisk": 80,
                    "otherNumAffected": 12,
                    "otherNumAtRisk": 80
                },
                {
                    "id": "EG002",
                    "title": "Double-blind TRx0237 16 mg/Day",
                    "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily in the double-blind phase",
                    "deathsNumAffected": 1,
                    "deathsNumAtRisk": 252,
                    "seriousNumAffected": 18,
                    "seriousNumAtRisk": 252,
                    "otherNumAffected": 22,
                    "otherNumAtRisk": 252
                },
                {
                    "id": "EG003",
                    "title": "Open-label TRx0237 16 mg/Day",
                    "description": "TRx0237 16 mg/day: Oral TRx0237 4-mg tablets administered twice daily in the open-label phase (all subjects who completed the double-blind phase and entered the open-label phase transitioned to receive this treatment)",
                    "deathsNumAffected": 8,
                    "deathsNumAtRisk": 449,
                    "seriousNumAffected": 27,
                    "seriousNumAtRisk": 449,
                    "otherNumAffected": 40,
                    "otherNumAtRisk": 449
                }
            ],
            "seriousEvents": [
                {
                    "term": "Anaemia",
                    "organSystem": "Blood and lymphatic system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Acute myocardial infarction",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Angina pectoris",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Atrial fibrillation",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cardiac failure",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Myocardial infarction",
                    "organSystem": "Cardiac disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Tympanic membrane perforation",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Vertigo positional",
                    "organSystem": "Ear and labyrinth disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Lens discolouration",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Vision blurred",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Abdominal pain upper",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Diverticulum",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Gastrointestinal haemorrhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Hiatus hernia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Incarcerated inguinal hernia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Inguinal hernia",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 2,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Retroperitoneal haemorrhage",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Small intestinal obstruction",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 2,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Vomiting",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Gait inability",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "General physical health deterioration",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cholelithiasis",
                    "organSystem": "Hepatobiliary disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Abdominal abscess",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Bronchitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cholecystitis infective",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Corona virus infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 2,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Diverticulitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Postoperative abscess",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Pyelonephritis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Respiratory syncytial virus bronchitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Sepsis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Urinary tract infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Urosepsis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Vestibular neuronitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Accidental overdose",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Costal cartilage fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Femoral neck fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Femur fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Head injury",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Hip fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Post procedural haematuria",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Radius fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Skeletal injury",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Spinal fracture",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Subdural haematoma",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Dehydration",
                    "organSystem": "Metabolism and nutrition disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Arthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Back pain",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Intervertebral disc degeneration",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Osteoarthritis",
                    "organSystem": "Musculoskeletal and connective tissue disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Bladder transitional cell carcinoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Colon cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Lung neoplasm malignant",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Malignant pleural effusion",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Metastasis",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Metastatic squamous cell carcinoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Non-small cell lung cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Papillary renal cell carcinoma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Plasma cell myeloma",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Prostate cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Tumour compression",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cauda equina syndrome",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cerebral haemorrhage",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Cerebrovascular accident",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Metabolic encephalopathy",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Normal pressure hydrocephalus",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Parkinsonism",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Presyncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Psychomotor hyperactivity",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Seizure",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Syncope",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Aggression",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Agitation",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Delirium",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Neuropsychiatric symptoms",
                    "organSystem": "Psychiatric disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 2,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Acute kidney injury",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Bladder disorder",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Haematuria",
                    "organSystem": "Renal and urinary disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Aspiration",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Chronic obstructive pulmonary disease",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Pulmonary embolism",
                    "organSystem": "Respiratory, thoracic and mediastinal disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 1,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 1,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 0,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Circulatory collapse",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Peripheral venous disease",
                    "organSystem": "Vascular disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 0,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 0,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 1,
                            "numAtRisk": 449
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Corona virus infection",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 6,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 7,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 18,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Fall",
                    "organSystem": "Injury, poisoning and procedural complications",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 11,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 2,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 5,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 15,
                            "numAtRisk": 449
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 20.1",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 8,
                            "numAtRisk": 266
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 5,
                            "numAtRisk": 80
                        },
                        {
                            "groupId": "EG002",
                            "numAffected": 10,
                            "numAtRisk": 252
                        },
                        {
                            "groupId": "EG003",
                            "numAffected": 9,
                            "numAtRisk": 449
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictiveAgreement": true
            },
            "pointOfContact": {
                "title": "Sotereos Gates, PhD",
                "organization": "TauRx Therapeutics Management Ltd.",
                "email": "s.gates@taurx.com",
                "phone": "+44 (0) 7771 570707"
            }
        }
    },
    "target_category": "disease-targeted small molecule",
    "drug": [
        "TRx0237",
        "LMTM",
        "leuco-methylthioninium bis(hydromethanesulfonate)",
        "leucomethylene blue",
        "hydromethylthioninium"
    ],
    "placebo": [
        "placebo"
    ],
    "explanation_target": [
        "Reason: The investigational product TRx0237 is described as a therapy given to subjects with Alzheimer\u2019s and the study includes a delayed-start/open-label phase intended to demonstrate a disease-modifying effect, which implies the drug targets core disease biology rather than only symptoms. \ue200cite\ue202turn0search3\ue201",
        "Act: TRx0237 is the small-molecule tau aggregation inhibitor leuco-methylthioninium (LMTM / leucomethylene blue / hydromethylthioninium); multiple sources describe TRx0237/LMTM as an inhibitor of tau aggregation and a stabilized/reduced derivative of methylene blue. This identifies it as a disease-targeted small molecule acting on tau pathology. \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Act (trial details): The trial text (randomized, double-blind, placebo-controlled monotherapy with a 12-month blinded phase followed by a 12-month open-label delayed-start) matches listings for TRx0237 clinical studies in Alzheimer\u2019s disease. \ue200cite\ue202turn0search3\ue202turn0search2\ue201",
        "Reflect: Given the drug is a small-molecule tau aggregation inhibitor (not a biologic like an antibody, and not described as purely symptomatic/cognitive enhancer or a psychiatry-targeted agent), the correct category is 'disease-targeted small molecule'. The classification aligns with the mechanism (tau aggregation inhibition) and the trial's disease-modifying intent. \ue200cite\ue202turn0search4\ue202turn0search5\ue201",
        "Web-search results (key sources used): 1) Trial listing for this study (TRx0237 monotherapy with open-label delayed start / NCT/registry entry). \ue200cite\ue202turn0search3\ue201 2) Chemical/functional description showing TRx0237 (LMTM) inhibits tau aggregation. \ue200cite\ue202turn0search4\ue202turn0search5\ue201 3) Registry/overview pages of TRx0237 / LMTM Phase 3 programs and extension studies. \ue200cite\ue202turn0search2\ue202turn0search1\ue201"
    ],
    "agent_type": "B) Tau",
    "explanation_agent": [
        "Reason: The study drug TRx0237 (also called LMTM, leuco-methylthioninium / hydromethylthioninium) is described as a disease-targeted small molecule intended to produce a disease\u2011modifying effect in Alzheimer\u2019s disease. Multiple published and registry sources identify TRx0237/LMTM as a tau aggregation inhibitor, i.e., it acts on tau pathology rather than only symptomatic neurotransmitter systems. \ue200cite\ue202turn0search1\ue202turn0search7\ue201",
        "Act: Extracted details \u2014 drug names: TRx0237, LMTM, leuco\u2011methylthioninium bis(hydromethanesulfonate), hydromethylthioninium. Mechanism: small\u2011molecule inhibitor of tau aggregation / tau aggregation inhibitor (stabilized reduced form of methylthioninium). Trial details: randomized double\u2011blind placebo\u2011controlled monotherapy with a delayed\u2011start/open\u2011label phase are consistent with TRx0237 clinical programs and long\u2011term safety/efficacy follow\u2011up studies. \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 this intervention directly targets tau aggregation (a core molecular pathology in AD). Although some secondary or pleiotropic effects (e.g., effects on autophagy or other protein aggregation processes) have been reported, the principal, stated mechanism and development rationale is anti\u2011tau aggregation activity. Therefore the appropriate CADRO category is B) Tau. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Web search results (key sources used): 1) Phase\u20113 randomized trial describing LMTM as a tau aggregation inhibitor and clinical development in AD. \ue200cite\ue202turn0search1\ue201 2) Mechanistic study and review describing leuco\u2011methylthioninium (LMT) activity against tau assembly. \ue200cite\ue202turn0search0\ue201 3) JACS Au / PMC mechanistic paper on methylthioninium effects on tau and notes on LMTM clinical development. \ue200cite\ue202turn0search3\ue201 4) Clinical trial/open\u2011label continuation listing for TRx0237 studies. \ue200cite\ue202turn0search4\ue201 5) Alzforum summary of HMTM/TRx0237 development and mechanism (tau aggregation inhibitor). \ue200cite\ue202turn0search7\ue201"
    ]
}